September 2026 results: higher sales, but half-year profit and cash flow weaken

Ebitda Margin ExpansionEbitda Margin CompressionNegative Operating CashflowResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+8.5%Reaction day

₹33.10

prior close

₹36.94

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.7%+6.7% vs market

Pharmaceuticals peers, median of 173sector+2.0%+6.5% vs sector

On the reaction day the stock moved 6.7 pts more than Nifty Microcap 250 and 6.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-4.7

10m

-0.9

15m

-0.9

30m

-2.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+8.5+1.7+6.7+2.0+6.5

Next day

+11.4+1.8+9.6+2.6+8.7

+8.0+2.5+5.5+2.6+5.4

+0.5pendingpending+2.0-1.6

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

For the quarter ended 30 September 2026, revenue rose 10.1% year on year to Rs 12,979.28 lakh and profit was Rs 191.09 lakh versus Rs 189.84 lakh, after a Rs 166.80 lakh loss in June quarter. For the half year, revenue rose 4.5% to Rs 25,574.09 lakh, but profit fell 93.2% to Rs 24.29 lakh from Rs 357.19 lakh. Operating cash flow was negative Rs 541.30 lakh versus positive Rs 1,388.75 lakh.

Likely market impact

Q2 profit was nearly flat despite higher sales, while first-half profit and operating cash flow weakened sharply, keeping near-term sentiment cautious.